Delving into the Latest Updates on RC1416 with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

RC14/16(Regenecore), Recombinant anti-human IL-4Rα and IL-5 single domain antibody(Regenecore), RC 1416

+ [2]

Target

IL-4Rα x IL-5

Action

inhibitors

Mechanism

IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors), IL-5 inhibitors(Interleukin-5 inhibitors)

Therapeutic Areas

Immune System DiseasesRespiratory DiseasesCongenital Disorders+ [1]

Active Indication

Moderate asthmaSevere asthmaModerate chronic obstructive pulmonary disease+ [3]

Inactive Indication-

Originator Organization

RegeneCore Biotech Co., Ltd

Active Organization

RegeneCore Biotech Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of RC1416 injection in patients with moderate to severe asthma Secondary objective: To evaluate the PK characteristics, PD characteristics, immunogenicity, and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma

Start Date22 Oct 2024

Sponsor / Collaborator

RegeneCore Biotech Co., Ltd

NCT06067490

/ CompletedPhase 1

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, andImmunogenicity of RC1416 Injection Via Subcutaneous Administration in Healthy Adult Volunteers.

This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.

Start Date29 Jun 2023

Sponsor / Collaborator

RegeneCore Biotech Co., Ltd

100 Clinical Results associated with RC1416

Login to view more data

100 Translational Medicine associated with RC1416

Login to view more data

100 Patents (Medical) associated with RC1416

Login to view more data

100 Deals associated with RC1416

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate asthma	Phase 1	China	RegeneCore Biotech Co., Ltd	29 Jun 2023
Severe asthma	Phase 1	China	RegeneCore Biotech Co., Ltd	29 Jun 2023
Moderate chronic obstructive pulmonary disease	IND Approval	China	RegeneCore Biotech Co., Ltd	03 Jan 2025
Moderate Atopic Dermatitis	IND Approval	China	RegeneCore Biotech Co., Ltd	25 Dec 2024
Severe Atopic Dermatitis	IND Approval	China	RegeneCore Biotech Co., Ltd	25 Dec 2024
Asthma	IND Approval	United States	RegeneCore Biotech Co., Ltd	10 Apr 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data